Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1177/1060028020953631 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Combined bictegravir, emtricitabine and tenofovir alafenamide for treating people with HIV: a plain language summary of the BICSTaR study up to 1 year.
Future Microbiol
October 2024
Hôpital Guy Chatiliez, Tourcoing, France.
What Is This Summary About?: This is a summary of an article about an ongoing study called the BICSTaR study.The BICSTaR study includes people with HIV (human immunodeficiency virus) who are taking a medicine called bictegravir/emtricitabine/tenofovir alafenamide (shortened to B/F/TAF). B/F/TAF is a single tablet that contains 3 different drugs for the treatment of HIV.
View Article and Find Full Text PDFB/F/TAF forgiveness to non-adherence.
Sex Transm Infect
October 2024
Department of Health Sciences, Infectious Disease Clinic, Università degli Studi di Genova, Genova, Italy.
: Background : ART forgiveness is the ability of a regimen to maintain HIV-RNA suppression despite a documented imperfect adherence. We explored forgiveness of bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF). : Methods : In this retrospective cohort study pharmacy drug refills were used to calculate the proportion of days covered (PDC) as a proxy of adherence.
View Article and Find Full Text PDFReal-Life Experience With Bictegravir/Emtricitabine/Tenofovir Alafenamide in Turkey.
Cureus
October 2023
Infectious Diseases and Clinical Microbiology, Akdeniz Sağlık Vakfı Yaşam Hospital, Antalya, TUR.
Introduction: Single-tablet regimens (STRs) can increase treatment success and even improve the quality of life of human immunodeficiency virus (HIV) patients. In this study, we aim to analyze the real-life efficacy and tolerability data of people living with HIV (PLWH) initiated on or switched to bictegravir/emtricitabine/tenofovir alafenamide fumarate (BIC/FTC/TAF) as first-line treatment.
Materials And Methods: This retrospective analysis was performed in HIV-1-positive patients who were initiated BIC/FTC/TAF in the HIV clinic between June 2020 and June 2022.
Optimizing Antiretroviral Therapy with Bictegravir/Emtricitabine/Tenofovir Alafenamide in virologically suppressed PLWH.
New Microbiol
September 2023
Infectious Diseases Department, University Tor Vergata, Rome, Italy.
The pillar of treatment success, defined as viral suppression and immune restoration, should be integrated into a modern vision of therapeutic success with pharmacological attributes of ART, such as potency, forgiveness, and genetic barrier of single drugs and regimens, as well as their longterm tolerability and safety. Moreover, the longterm success of lifelong treatment cannot be separated from the opinions and preferences of PLWH. Regimen Optimization in the setting of HIV suppression may reduce pill burden, and/or dosing frequency, enhance tolerability and/or decrease toxicity, prevent or mitigate DDIs, eliminate food/fluid requirements, relieve pill fatigue, decrease stigma or concerns associated with taking oral med, allow pregnancy, reduce costs (DHHS 2023).
View Article and Find Full Text PDFSwitching to bictegravir/emtricitabine/tenofovir alafenamide (BIC/FTC/TAF) plus darunavir/cobicistat in heavily antiretroviral-experienced, virologically suppressed HIV-infected adults receiving complex regimens.
J Antimicrob Chemother
November 2023
Department of Infectious Diseases, Hospital Universitario Reina Sofia, Instituto Maimónides de Investigación Biomédica de Córdoba (IMIBIC), Universidad de Córdoba (UCO), Córdoba, Spain.
Article Synopsis
- The study assessed the safety and effectiveness of a two-pill HIV treatment regimen (BIC/FTC/TAF plus darunavir/cobicistat) for individuals with a history of treatment difficulties.
- The trial had 63 participants, mainly men, who were stable on a more complex regimen and showed high rates of maintaining low viral loads after 48 weeks.
- Results indicated the new regimen is well-tolerated, potentially enhancing adherence and long-term success in managing HIV for heavily treatment-experienced individuals.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!